“A” health bomb. The French pharmaceutical laboratory Servier announced to enter into exclusive negotiation with the British investment fund BC Partners to sell its subsidiary Biogaran. Biogaran is the leader in generic drugs in France, present up to a third of those sold in our pharmacies. Health economist Frédéric Bizard described the news of “slow -blast political bomb”.
Guest on RTL this Friday, August 1, LA Senator (Centrist Union) of Calvados Sonia Delaprovotéewho is president of the senatorial commission of inquiry into the shortage of drugs, explains on RTL that the threat which weighs after this announcement is multiple. “This is an element that is not going to be neutral at all on the future of the availability of generic drugs on our territory,” she says. There are several threats. The first, of course, is the threat of public health. That is, the availability of drugs, its genericswhich represent a very large part of the availability of generics in France, especially since Biogaran, it is a lot of therapeutic classes with completely essential drugs, antibiotics in paracetamol. “
“The second subject, she continues, is the risk of shortage. The third is Employment and industrial imprint. Because Biogaran, we are more than 8,000 direct and indirect jobs with a French headquarters. It is a real attachment to availability, to the production of drugs on our territory “.
According to the senator, in this case, “we touch an essential segment of drug availability, since we touch the credits”. “The credits are the basis of a large part of health savings, Since they are cheaper drugs to reimburse. If we do not have the availability of credits and we do not have the availability of other drugs, at that time, we have a less therapeutic management, even renunciations for care. The consequences in terms of health economy are essential and in health matters, the needs to recall are absolutely major “.
